{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:21:48Z","timestamp":1789154508076,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.idcr.2025.e02191","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:17:32Z","timestamp":1740557852000},"page":"e02191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Organizing pneumonia in a patient following treatment of chronic hepatitis B with pegylated interferon alfa-2b: A case report"],"prefix":"10.1016","volume":"39","author":[{"given":"Bing","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-0188","authenticated-orcid":false,"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.idcr.2025.e02191_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","article-title":"Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission","volume":"5","author":"Sarin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.idcr.2025.e02191_bib2","first-page":"938","volume":"27","author":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version)","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"4","key":"10.1016\/j.idcr.2025.e02191_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1665-2681(19)31348-1","article-title":"Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports","volume":"12","author":"Hegade","year":"2013","journal-title":"Ann Hepatol"},{"issue":"9","key":"10.1016\/j.idcr.2025.e02191_bib4","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1111\/j.1572-0241.2002.05999.x","article-title":"Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C","volume":"97","author":"Kumar","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.idcr.2025.e02191_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/01.MAJ.0000308932.93221.68","article-title":"T cells subtypes in a patient with interferon-alpha induced sarcoidosis","volume":"337","author":"Monsuez","year":"2009","journal-title":"Am J Med Sci"},{"issue":"7","key":"10.1016\/j.idcr.2025.e02191_bib6","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/jhm.452","article-title":"Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C","volume":"4","author":"Arora","year":"2009","journal-title":"J Hosp Med"},{"issue":"4","key":"10.1016\/j.idcr.2025.e02191_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4065\/74.4.367","article-title":"Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C","volume":"74","author":"Bini","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.idcr.2025.e02191_bib8","doi-asserted-by":"crossref","unstructured":"Wu Z.Q., Xie D., Fu L., Wei J., Shang J., He Q., et al. Functional cure based on pegylated interferon \u0251-2b in long-term nucleoside analog suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest project in China), an interim report. 2020.","DOI":"10.1016\/S0168-8278(20)32210-8"},{"issue":"26","key":"10.1016\/j.idcr.2025.e02191_bib9","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.idcr.2025.e02191_bib10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.idcr.2025.e02191_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1478-3231.2010.02384.x","article-title":"Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?","volume":"31","author":"Sonneveld","year":"2011","journal-title":"Liver Int: J Int Assoc Study Liver"},{"issue":"35","key":"10.1016\/j.idcr.2025.e02191_bib12","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.3748\/wjg.v16.i35.4394","article-title":"Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C","volume":"16","author":"Ji","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.idcr.2025.e02191_bib13","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/425746","article-title":"Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature","volume":"39","author":"Midturi","year":"2004","journal-title":"Clin Infect Dis: Publ Infect Dis Soc Am"},{"issue":"3","key":"10.1016\/j.idcr.2025.e02191_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10620-009-0797-1","article-title":"Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature","volume":"55","author":"Slavenburg","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"1 1","key":"10.1016\/j.idcr.2025.e02191_bib15","first-page":"3","article-title":"A perspective on the clinical effectiveness and tolerance of interferon-alpha","volume":"25","author":"Borden","year":"1998","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.idcr.2025.e02191_bib16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/gast.1997.v112.pm9041265","article-title":"New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine","volume":"112","author":"Tilg","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.idcr.2025.e02191_bib17","first-page":"277","article-title":"This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","author":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias","year":"2002","journal-title":"Am J Respir Crit Care Med"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250925000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250925000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T05:58:06Z","timestamp":1744523886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250925000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":17,"alternative-id":["S2214250925000460"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2025.e02191","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organizing pneumonia in a patient following treatment of chronic hepatitis B with pegylated interferon alfa-2b: A case report","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2025.e02191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e02191"}}